Agios Pharmaceuticals Inc (NASDAQ:AGIO) has been given an average rating of “Buy” by the sixteen brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twelve have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $63.18.

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Agios Pharmaceuticals in a research note on Tuesday, November 26th. They issued an “overweight” rating and a $64.00 target price for the company. Piper Jaffray Companies decreased their target price on shares of Agios Pharmaceuticals from $80.00 to $70.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. JPMorgan Chase & Co. decreased their target price on shares of Agios Pharmaceuticals from $80.00 to $68.00 and set an “overweight” rating for the company in a research note on Wednesday, December 4th. Cowen reissued a “buy” rating on shares of Agios Pharmaceuticals in a research note on Tuesday. Finally, BMO Capital Markets lifted their price objective on shares of Agios Pharmaceuticals from $45.00 to $49.00 and gave the stock an “outperform” rating in a research report on Monday, December 9th.

Shares of NASDAQ AGIO traded up $1.31 during midday trading on Friday, reaching $52.86. The company’s stock had a trading volume of 1,600,573 shares, compared to its average volume of 908,496. The company has a current ratio of 5.30, a quick ratio of 5.24 and a debt-to-equity ratio of 0.24. Agios Pharmaceuticals has a fifty-two week low of $28.36 and a fifty-two week high of $68.94. The stock has a market capitalization of $3.09 billion, a price-to-earnings ratio of -8.77 and a beta of 2.35. The stock has a 50 day simple moving average of $46.34 and a 200-day simple moving average of $40.53.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.85) by $0.04. Agios Pharmaceuticals had a negative net margin of 356.42% and a negative return on equity of 70.07%. The company had revenue of $26.02 million for the quarter, compared to the consensus estimate of $33.13 million. During the same period last year, the company earned ($1.63) earnings per share. The firm’s revenue was up 71.2% compared to the same quarter last year. As a group, equities analysts anticipate that Agios Pharmaceuticals will post -6.85 EPS for the current year.

In other Agios Pharmaceuticals news, insider Carman Alenson sold 2,950 shares of Agios Pharmaceuticals stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $50.09, for a total transaction of $147,765.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Corp /De/ Celgene acquired 403,225 shares of Agios Pharmaceuticals stock in a transaction on Tuesday, November 12th. The shares were bought at an average cost of $31.00 per share, with a total value of $12,499,975.00. Following the completion of the transaction, the insider now owns 1,777,824 shares of the company’s stock, valued at $55,112,544. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 451,611 shares of company stock valued at $13,999,941. Company insiders own 3.16% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Northern Trust Corp boosted its position in shares of Agios Pharmaceuticals by 20.5% in the second quarter. Northern Trust Corp now owns 299,654 shares of the biopharmaceutical company’s stock valued at $14,947,000 after acquiring an additional 50,908 shares during the period. BlackRock Inc. boosted its position in shares of Agios Pharmaceuticals by 30.8% in the second quarter. BlackRock Inc. now owns 4,362,184 shares of the biopharmaceutical company’s stock valued at $217,585,000 after acquiring an additional 1,027,819 shares during the period. California Public Employees Retirement System boosted its position in shares of Agios Pharmaceuticals by 40.9% in the third quarter. California Public Employees Retirement System now owns 86,400 shares of the biopharmaceutical company’s stock valued at $2,799,000 after acquiring an additional 25,100 shares during the period. State of New Jersey Common Pension Fund D bought a new stake in shares of Agios Pharmaceuticals in the third quarter valued at about $1,649,000. Finally, Morgan Stanley boosted its position in shares of Agios Pharmaceuticals by 36.1% in the second quarter. Morgan Stanley now owns 79,556 shares of the biopharmaceutical company’s stock valued at $3,967,000 after acquiring an additional 21,107 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Further Reading: How Do You Calculate Return on Equity (ROE)?

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.